This collection of content will continually bring you the latest news, research and FDA approvals relating to leukemia and lymphoma.
New! 'Exciting' Clinical Trials
MD Anderson’s Tapan Kadia, MD, highlights a few clinical trials that have the potential to change the standards of care.
Predictions for Next Achievement in Leukemia
Tapan Kadia, MD, associate professor, Department of Leukemia, MD Anderson Cancer Center, is hopeful that the next big milestone “will be the cure of one of these diseases.”
New! Blog: The Evolving Treatment of Chronic Lymphocytic Leukemia
Over the past 5 years, the field of chronic lymphocytic leukemia (CLL) has seen the emergence of multiple new classes of therapies, including Bruton’s tyrosine kinase (BTK) inhibitors, phosphatidylinositol-3-kinase (PI3K) inhibitors, and BCL-2 inhibitors.
CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
New data was recently presented at the 2018 ASH Annual Meeting for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), including promising clinical results in follicular lymphoma (FL).
Positive Results for CT-P10 as Treatment for Advanced Follicular Lymphoma
New data shows that the efficacy and safety of CT-P10 is comparable to reference rituximab in patients with advanced follicular lymphoma (AFL) over 2 years. The findings were presented at the 2018 ASH Annual Meeting.